- Home
- NATL vs AKRO Comparison
NATL vs AKRO Comparison
Compare NATL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATL
- AKRO
- Stock Information
- Founded
- NATL 2023
- AKRO 2017
- Country
- NATL United States
- AKRO United States
- Employees
- NATL N/A
- AKRO N/A
- Industry
- NATL
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- NATL
- AKRO Health Care
- Exchange
- NATL Nasdaq
- AKRO Nasdaq
- Market Cap
- NATL 1.8B
- AKRO 3.9B
- IPO Year
- NATL N/A
- AKRO 2019
- Fundamental
- Price
- NATL $29.86
- AKRO $52.40
- Analyst Decision
- NATL Buy
- AKRO Strong Buy
- Analyst Count
- NATL 4
- AKRO 6
- Target Price
- NATL $38.75
- AKRO $82.50
- AVG Volume (30 Days)
- NATL 450.1K
- AKRO 1.7M
- Earning Date
- NATL 08-12-2025
- AKRO 08-08-2025
- Dividend Yield
- NATL N/A
- AKRO N/A
- EPS Growth
- NATL N/A
- AKRO N/A
- EPS
- NATL 1.55
- AKRO N/A
- Revenue
- NATL $4,247,000,000.00
- AKRO N/A
- Revenue This Year
- NATL $1.81
- AKRO N/A
- Revenue Next Year
- NATL $4.37
- AKRO N/A
- P/E Ratio
- NATL $19.34
- AKRO N/A
- Revenue Growth
- NATL N/A
- AKRO N/A
- 52 Week Low
- NATL $22.30
- AKRO $21.34
- 52 Week High
- NATL $35.50
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- NATL 61.43
- AKRO 52.50
- Support Level
- NATL $28.19
- AKRO $50.13
- Resistance Level
- NATL $31.11
- AKRO $52.73
- Average True Range (ATR)
- NATL 0.92
- AKRO 2.09
- MACD
- NATL 0.08
- AKRO -0.76
- Stochastic Oscillator
- NATL 71.00
- AKRO 34.00
About NATL NCR Atleos Corporation
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.